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Table 1. Comparison of outcomes of patients with extensively drug-resistant (XDR) and multidrug-resistant (MDR) tuber-
culosis (TB).
Outcome
Results of Kim et al. [1] Results of Migliori et al. [3]
No. (%) of patients Univariate analysis No. (%) of patients Univariate analysis
XDR TB
(n p 43)
MDR TB
(n p 168) RR (95% CI) P
XDR TB
(n p 64)
MDR TB
(n p 361) RR (95% CI) P
Treatment success
Overall 23 (53.5) 109 (64.9) 22 (34.4) 165 (45.7)
Cured 23 (53.5) 84 (50.0) 19 (29.7) 134 (37.1)
Treatment completed … 25 (14.9) 3 (4.7) 31 (8.6)
Treatment failure
Overall 19 (44.2) 46 (27.4) 1.68 (0.99–2.85) .057 26 (40.6) 75 (20.8) 2.19 (1.31–3.66) .002
Relapse 2 (4.7) 4 (2.4) 0 0
Failure 11 (25.6) 29 (17.3) 1.58 (0.84–2.95) .16 12 (18.7) 32 (8.9) 2.32 (1.24–4.32) .008
Death 6 (14.0) 13 (7.7) 1.81 (0.85–3.87) .143 14 (21.9) 43 (11.9) 2.09 (1.14–3.81) .017
NOTE. RR, relative risk.
suppression, whereas 28 did not achieve
viral suppression at 1 year after initiation
of therapy.
Thus, our results suggest that hospital-
ization at the time of starting HAART is
an additional factor favoring adherence.
The following 3 underlying variables may
have favored adherence to therapy: diag-
nosis of AIDS and, therefore, fear of death;
rapid clinical improvement while receiv-
ing treatment; and immediate reassurance
by physicians and nurses when patients
experienced adverse effects during hospi-
talization. It remains to be seen whether
such positive effects of initial hospitali-
zation can be maintained during long-
term follow-up.
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Extensively Drug-Resistant
Tuberculosis Is Worse than
Multidrug-Resistant
Tuberculosis: Different
Methodology and Settings,
Same Results
To the Editor—We read with interest
the article by Kim et al. [1] about the im-
pact of extensively drug-resistant (XDR)
tuberculosis (TB) on treatment outcomes
of non–HIV-infected patients affected by
multidrug-resistant (MDR) TB. Kim et al.
[1] found, with univariate analysis, that
patients with XDR TB had a borderline-
significant higher probability of treatment
failure and death than did patients with
MDR TB (table 1). Multivariate analysis
confirmed that XDR TB is a poor inde-
pendent prognostic factor for treatment
failure (OR, 4.46; 95% CI, 1.35–14.74).
Two studies from our group had previ-
ously reached similar conclusions [2, 3].
Our first study found that patients with
XDR TB in Italy and Germany, compared
with patients with MDR TB, had a 5-fold
increase in the risk of death (relative risk,
5.45; 95% CI, 1.95–15.27; ), re-P ! .01
quired longer hospitalization (mean du-
ration  SD, vs.241.2 177.0 99.1
days; ), had longer treatment85.9 P ! .001
duration ( vs.30.3 29.4 15.0 23.8
months; ), and, for the few patientsP ! .05
whose sputum and smear converted from
positive to negative, a longer time to smear
or culture conversion ( ) [2]. TheP ! .01
second study (including additional pa-
tients from Estonia and Russia) found that
patients with XDR TB had a relative risk
of 1.58 to die or have treatment failure,
compared with patients with MDR TB re-
sistant to all first-line drugs (95% CI,
1.14–2.20; ), and a relative risk ofP ! .05
2.61 (95% CI, 1.45–4.69; ), com-P ! .001
pared with patients with MDR TB for
whom susceptibility to 1 first-line drug
still existed [3]. Interestingly, the results of
the studies from the 2 groups are consis-
tent, although the definitions used were
slightly different: Migliori et al. [2] used
the World Health Organization definitions
of treatment success and failure [4, 5], and
Kim et al. [1] applied the definitions pro-
posed by Laserson et al. [6]. Furthermore,
Kim et al. [1] (and not Migliori et al. [2])
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included death with treatment failure. To
make a contribution toward the use of
standardized definitions and to allow a
better comparison of the data from the 2
groups, we recalculated our treatment out-
comes from the 4-country study on the
basis of the methodology of Kim et al. [1]
(table 1). With the univariate analysis, pa-
tients with XDR TB had a significantly
higher probability of treatment failure
than did patients with MDR TB (relative
risk, 2.19; 95% CI, 1.31–3.66; ).Pp .002
According to our data, patients with XDR
TB had a higher probability of death and
treatment failure than did patients with
MDR TB, even when the 2 outcomes were
analyzed separately (table 1). With the
multiple regression analysis, the presence
of XDR was an independent risk factor for
both death (OR, 2.07; 95% CI 1.05–4.05;
) and treatment failure (OR, 2.37;P ! .034
95% CI, 1.14–4.89; ).P ! .02
The different findings related to some
of the patient characteristics of the 2 data
sets (e.g., radiography findings, number of
drugs, and treatment duration) suggest
that our patients with MDR TB (especially
those from Eastern Europe) have more-
severe disease than do those of Kim et al.
[1]. Moreover, the consistency of out-
comes from both studies suggests that (1)
results are robust and (2) XDR TB has a
negative clinical and prognostic signifi-
cance, even in patients with different sus-
ceptibility profiles and from different set-
tings (e.g., Korea and Eastern and Western
Europe). While we wait for the develop-
ment of new drugs and rapid diagnostic
procedures, there should be a prompt and
globally coordinated public health re-
sponse, to prevent further development of
drug resistance.
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